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The present study determined the pharmacokinetic profile of vancomycin in premature Malaysian infants.
A one-compartment infusion model with first-order elimination was fitted to serum vancomycin concentration
data (n  835 points) obtained retrospectively from the drug monitoring records of 116 premature newborn
infants. Vancomycin concentrations were estimated by a fluorescence polarization immunoassay. Population
and individual estimates of clearance and distribution volume and the factors which affected the variability
observed for the values of these parameters were obtained using a population pharmacokinetic modeling
approach. The predictive performance of the population model was evaluated by visual inspections of diag-
nostic plots and nonparametric bootstrapping with replacement. Dosing guidelines targeting a value of >400
for the area under the concentration-time curve over 24 h in the steady state divided by the MIC (AUC24/MIC
ratio) were explored using Monte Carlo simulation. Body size (weight), postmenstrual age, and small-
for-gestational-age status are important factors explaining the between-subject variability of vancomycin
pharmacokinetic parameter values for premature neonates. The typical population parameter estimates of
clearance and distribution volume for a 1-kg premature appropriate-for-gestational-age neonate with a
postmenstrual age of 30 weeks were 0.0426 liters/h and 0.523 liters, respectively. There was a 20% reduction in
clearance for small-for-gestational-age infants compared to the level for the appropriate-for-gestational-age
control. Dosage regimens based on a priori target response values were formulated. In conclusion, the
pharmacokinetic parameter values for vancomycin in premature Malaysian neonates were estimated. Im-
proved dosage regimens based on a priori target response values were formulated by incorporating body size,
postmenstrual age, and small-for-gestational-age status, using Monte Carlo simulations with the model-
estimated pharmacokinetic parameter values.
Bacterial sepsis is a major cause of neonatal complications,
prolonged hospital stay, and death in premature newborns,
especially those in developing countries. Sepsis-related mor-
tality and morbidity rates were even higher in extremely
preterm neonates and intrauterine-growth-restricted infants
because of their innate immunological immaturity (36). Be-
cause coagulase-negative staphylococcus (CoNS) is a com-
mon pathogen for late-onset (72-h-postbirth) septicemia, and
because methicillin-resistant Staphylococcus aureus (MRSA) is
an important pathogen (10), vancomycin continues to be
widely prescribed in neonatal intensive care units.
Kidney and vestibular/cochlear damage is a concern associ-
ated with vancomycin use. Very recently, it was shown that
vancomycin trough concentrations were correlated with nephro-
toxicity in hospitalized adult patients (27). Nonetheless, van-
comycin-associated ototoxicity and nephrotoxicity among neo-
nates are thought to be less frequent than those in adults (11),
although more evidence-based investigations using appropri-
ately designed and powered studies are needed. Until such
data are forthcoming, it is prudent to avoid exposure to un-
necessarily high peak or trough concentrations of vancomycin
in the premature newborn.
There remain conflicting recommendations regarding the
therapeutic range and monitoring practices that apply to van-
comycin pharmacotherapy (20, 34, 37). Traditionally, for inter-
mittent administration, various permutations of dose and dose
frequency are often faithfully applied in order to obtain trough
and peak plasma concentrations of 5 to 10 mg/liter and 20 to 50
mg/liter, respectively (37). Others have suggested that plasma
trough concentrations of 10 to 15 mg/liter (23) or 15 to 20
mg/liter (18) may be suitable with respect to toxicity and effi-
cacy against MRSA. One recent study (24) failed to demon-
strate enhanced vancomycin efficacy in patients with MRSA
infections when there were elevated plasma trough concen-
trations of 15 to 20 mg/liter. Other studies found vancomy-
cin to be more efficacious against invasive MRSA when the
ratio of the area under the concentration-time curve over 24
h (AUC24) to the MIC was at least 400 h (AUC24/MIC ratio of
400) (16, 28, 34).
There are no reports correlating vancomycin bactericidal
effect and systemic exposure to vancomycin in neonatal pa-
tients. All information regarding the drug concentrations and
efficacy response is, therefore, based on data derived from
adult populations and extrapolated to the pediatric/neonatal
population.
Malaysian infants are generally born smaller than their Cau-
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casian counterparts. So far, there have been no data on the
pharmacokinetics of vancomycin in very premature Malaysian
neonates, despite the widespread use of this antibiotic in that
country. Dosing practices have relied solely on literature data
from Caucasian infants. Besides elucidating any alteration in
pharmacokinetic parameter values, it was important to obtain
estimates of the variability in this population since high inter-
individual pharmacokinetic variability is a feature of antimi-
crobial pharmacotherapeutics in premature infants (33). Ac-
cordingly, the aim of present study was to conduct a population
pharmacokinetic analysis in order to obtain pharmacokinetic
data for vancomycin in premature Malaysian infants. These
findings were then applied using simulation to explore possi-
bilities for improved vancomycin dosage regimens.
(Part of this work was presented at the PAGANZ [Popula-
tion Approach Group of Australia and New Zealand] Scien-
tific Meeting in February 2010.)
MATERIALS AND METHODS
Ethics and patient characteristics. The study protocol was approved by the
Medical Ethics Committee of the University of Malaya Medical Centre. Data
were collected retrospectively from the records of the Special Care Nursery,
(SCN), University of Malaya Medical Centre, Kuala Lumpur, Malaysia, from
1999 to 2005. Data on gestational age (GA), postmenstrual age (PMA), postnatal
age (PNA), birth weight (BW), current weight (WT), Apgar scores (APG), and
other concurrent treatment (CT) as well as laboratory clinical data were ex-
tracted from medical records. Infants having GAs of less than 32 weeks and
PMAs of less than 36 weeks and having each had at least 2 vancomycin serum
determinations performed were considered for inclusion in the study. An infant
was considered to be small for gestational age (SGA) if the BW was below the
10th percentile of a specific weight threshold for a specific GA according to the
fetal growth weight standard (29) for Singapore infants, since no Malaysian data
on body weight for neonates born before the 28-week gestation were available.
Vancomycin dosing, blood sampling, and measurement. A vancomycin hydro-
chloride concentration (10 mg/ml) in normal saline for intravenous administra-
tion was reconstituted in the hospital pharmacy and infused at a constant rate
over 60 min via a programmed syringe driver. Blood samples were collected by
capillary heel pricking into clotting tubes and the sera isolated by centrifugation.
Serum vancomycin concentrations were determined by a fluorescence polariza-
tion immunoassay method using the Cobas Integra 800 system from Roche
Diagnostics, Switzerland. The lower detection limit of this assay was 1.39 mg/
liter, and the between-day imprecision values (coefficients of variation [CV%])
were 3.0% at 8.70 mg/liter and 3.3% at 54.6 mg/liter.
Population pharmacokinetic analysis. The pharmacokinetics from the con-
centration-time data were modeled by first-order conditional estimation with
interaction (FOCE-I), using NONMEM version 6.10 (5). An overview of popu-
lation modeling as implemented in NONMEM is described elsewhere (14). An
initial analysis was performed to estimate the parameter values for a base model
(i.e., no added covariates), and the influence of covariates was assessed by adding
these values to the base model in turn. The likelihood ratio test was used to
statistically assess the influence of covariates in improving the fit of a given model
to the data; a change in the objective function value (OFV), which is generated
in the NONMEM output, was noted for comparison of goodness-of-fit values
among competing nested covariate models. The difference between a pair of
OFV values observed when a covariate was included and then excluded was
tested for statistical significance (P  0.01). The difference between OFV values
approximates the chi-square statistic with 1 degree of freedom (21, 0.01  6.6).
The between-subject variability (BSV) was modeled assuming a log-normal
distribution, using the equation Pjk  PPOP  exp(j  k), where Pjk represents
the true but unknown value of a parameter, e.g., clearance (CL) or volume of
distribution (V), for the jth subject on the kth occasion, where PPOP is the
population mean value for a parameter, where j is a normally distributed
random variable having a variance of 12 and mean of 0, representing the
difference between a parameter value in the jth subject and PPOP, and where k
is a random variable used to represent the variability of a given pharmacokinetic
parameter value on different occasions (BOV), an occasion being defined a priori
as a dose or sequence of doses followed by at least 1 observation. The BOV was
assumed to be sampled from a normal distribution having a mean of 0 and a
variance of 22. In modeling the BOV, it was assumed that the variances of each
parameter were sampled from the same distribution. In this study, any sample
taken after an interval of 3 days was considered representative of a different
occasion, as concentration monitoring of vancomycin typically occurred 3 days
after initiation or change of dose.
The residual unexplained variability (RUV) among observed vancomycin con-
centrations and those predicted by the final population model were estimated
by a combined proportional-additive error model, using the equation Cij 
Cpred,ij  (1  ε1,ij)  ε2,ij, where Cij is the ith observed concentration in the jth
subject, Cpred,ij is the serum concentration predicted by the pharmacokinetic
model, and ε1,ij and ε2,ij are randomly distributed variables having mean values of
0 and variances of 12 and 22, respectively.
Model evaluation. The performance of the final covariate model was evaluated
by visual inspection of diagnostic scatter plots. The robustness of the model
was assessed using a nonparametric bootstrap, with replacement, of 1,000
NONMEM runs of the final model; the bootstrap median parameter values and the
percentile bootstrap 95% intervals were compared with the respective values
estimated from the final model.
Dosing regimen simulations. Serum vancomycin concentration-time data sets
for different dosing regimens were generated for 100 virtual infants with char-
acteristics similar to those observed for the study patients by use of Monte Carlo
simulation in conjunction with MASS (39) in R (version 2.8.1) (31). The final
model was then used to produce 1,000 simulations of the serum concentration-
time data for each patient’s data set. In view of the efficacies and toxicities in
relation to concentrations of vancomycin in serum, the criteria for recommended
dosing regimens were as follows: 80% of the predicted AUC24/MIC ratios at
400, predicted trough concentrations from 5 to 20 mg/liter, and peak concen-
trations of 50 mg/liter. AUC24 was calculated by dividing a 24-h dose by CL
TABLE 1. Baseline characteristics of all neonatesa
Demographic Mean  SD (range)
Total no. of
neonates
(%)
Gestational age (wk)
	24 23.0  0 2 (1.7)
24–28 26.4  1.3 66 (56.9)
29–31 29.7  0.85 48 (41.4)
Postmenstrual age (wk)
	24 23.6  0.4 2 (1.7)
24–28 26.3  1.1 39 (33.6)
28–32 29.8  1.1 70 (60.3)
32–34 32.7  0.7 5 (4.3)
Postnatal age (days)
1–7 4.3  1.6 86 (74.1)
8–14 10.3  1.8 21 (18.1)
15–21 16.5  1.8 6 (5.2)
22–28 25.0  2.8 2 (1.7)
29–32 32 1 (0.9)
Birth wt (kg)
	0.5 0.42 1 (0.9)
0.5–0.75 0.67  0.06 19 (16.4)
0.75–1.0 0.87  0.07 51 (44.0)
1.0–1.5 1.19  0.13 42 (36.2)
1.5–2 1.81  0.17 3 (2.6)
Study wt (kg)
0.5–0.75 0.67  0.09 25 (21.6)
0.75–1.0 0.91  0.1 55 (47.4)
1.0–1.5 1.20  0.13 33 (28.4)
1.5–2 1.77  0.23 3 (2.6)
Serum creatinine concn
(mmol/liter)
0.076  0.02 (0.031–0.143)
Apgar score at 1 min 5.0  2.0 (1–9)
Apgar score at 5 min 7.4  1.9 (2–10)
a n  116 (66 males; 40% small-for-gestational-age neonates).
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estimated by NONMEM from the simulation. The MIC for MRSA was set at 1
mg/liter, according to the Malaysian hospital’s institutional bacteriograms.
RESULTS
Patient characteristics. Data comprising 835 serum vanco-
mycin concentrations that were available for pharmacokinetic
analysis were obtained from 116 premature neonates, compris-
ing 105 single births, 4 twin births, and 1 triplet birth. More
than half (58%) of these neonates had gestational ages of 28
weeks or less. Among these neonates, 56% were Malays, 25%
Chinese, and 18% Indian and 2% had other racial back-
grounds, but all patients were of Asian heritage. The baseline
characteristics of the study subjects are summarized in Table 1.
Population pharmacokinetics. Both one- and two-compart-
ment models were fitted to the data. The two-compartment
model showed minimum advantages over the one-compart-
ment model. Furthermore, large standard errors of the param-
eter estimates for the peripheral distribution volume and
intercompartmental clearance revealed overparameterization
(results not shown). Therefore, the pharmacokinetics of van-
comycin was analyzed using a one-compartment open model
with zero-order dosing (1 h intravenous infusion) and first-order
elimination. Vancomycin concentrations versus sampling time af-
ter the last dose are presented in Fig. 1. A high correlation was
found between PMA and WT (r 0.64), and there was a negative
correlation between PMA and SCR (r  
0.51), while separate
correlations between SGA status and both WT and PMA were
less pronounced (r  0.34). In all covariate models, both CL
and V were allometrically scaled to the size standard of a 70-kg
adult to enable direct comparison with published adult values.
Allometric exponents of 0.75 and 1 were assumed for CL and V,
respectively (22), to uncouple correlations between size and
values for developmental parameters, such as PMA, WT, and
GA. The structural population model which best described the
data comprised the equations CL  1.0  (WT/70)0.75  (PMA/
30)3.16  [0.83  SGA  1.03  (1 
 SGA)] and V  36.6  WT/
70, where CL is clearance (liters/h), V is the apparent volume
of distribution (liters), PMA is the postmenstrual age (weeks),
and SGA is 1 for small-for-gestational-age infants and 0 for
appropriate-for-gestational-age infants.
The BSV values for both CL and V in the final model were
less than half those estimated using the base model, while the
proportional component of the RUV was reduced by more
than a third, indicating that the final model accounted for
much of the variability in the data (Table 2).
The typical population parameter estimates of CL and V for
a 1-kg premature neonate with a PMA of 30 weeks were 0.0426
liters/h and 0.523 liters, respectively. The estimated population
vancomycin elimination half-life was 8.5 h. There was a 20%
reduction in CL for SGA infants, compared to the level for
AGA infants. The BOV of CL was 16.7%; however, an esti-
mate of the BOV of V could not be supported by the data. The
correlation coefficient (r  0.6) between CL and V was esti-
mated from the values of the off-diagonal elements of the
covariance-variance matrix, thereby justifying the simultaneous
estimation of covariance and variances during the develop-
ment of the variability model. The estimated clearance values
in relation to the postmenstrual ages and postnatal ages of the
study subjects are displayed in Fig. 2.
FIG. 1. Scatter plot of vancomycin concentration versus time after
the last dose for all study subjects.
TABLE 2. Variance changes related to the model-building processa
Model Covariate(s) OFV BSVCL BSVV RUVprop RUVadd
Base None 0 43.6 30.5 36.3 1.41
1 Size on CL 
157 30.3 28.9 32.6 1.57
2 PMA on CL 
276 33.3 28.8 27.5 1.82
3 SCR on CL 
227 36.9 29.4 27.4 2.09
4 PNA on CL 
204 38.5 31.8 29.3 1.74
5 Ventilation on CL 
56 40.9 31.2 35.9 1.67
6 SGA on CL 0 43.4 30.5 36.3 1.41
7 NSAID on CL 0 43.5 31.2 36.3 1.99
8 Race on CL 
5 44.4 30.3 36.2 1.45
9 Size on V 
12 45.3 6.4 31.8 2.32
10 Size and PMA on CL; size on V 
449 23.3 12.0 23.0 1.52
12 Size, PMA, and race on CL; size on V 
458 23.1 12.5 23.0 1.52
13 Size, PMA, and SCR on CL; size on V 
426 23.1 10.8 22.9 2.18
Final Size, PMA, and SGA on CL; size on V 
519 20.5 12.6 22.9 1.51
a OFV, change in objective function values; BSV, between-subject variability; RUVprop, unexplained residual variability (proportional); RUVadd, unexplained
residual variability (additive); SCR, serum creatinine concentration.
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The plots of both the observed-versus-pre-Bayesian-estima-
tion (population-predicted) values and the observed-versus-
post-Bayesian-estimation (individual-predicted) values showed
that the data points were distributed closely and symmetrically
to the line of identity for the final model (Fig. 3). Box plots
depicting the distributions of the predose and postdose con-
centrations of observation and predicted concentrations from
1,000 simulations derived from the final model are presented
in Fig. 4. The median values for both the predose and the
postdose concentrations from the observed data and the pre-
diction as well as the interquartile range were similar, indicat-
ing the acceptable predictive capability of the final model.
Pharmacokinetic parameter estimates for the final model
and for the 1,000 bootstrap runs are presented in Table 3. For
each parameter used, the median value from the bootstrapping
runs was very close to the population median obtained using all
the data and lay within the percentile bootstrap 95% intervals,
indicating that the final model was stable and robust when the
model was fitted to various combinations of concentration-
time data sets.
Dosage regimen simulation. Data sets were simulated for
100 virtual infants with the following values (means standard
deviations [SD]): a weight of 1  0.84 kg, a PMA of 30  2.45
weeks, a correlation of WT and PMA of 0.64, and a probability
of SGA status of 0.4. A loading dose of 15 mg/kg of body
weight was administered if the maintenance doses were less
than 15 mg per dose. As illustrated in Table 4, when the
recommended dosage regimen for AGA infants was applied to
SGA infants, more than 30% of these infants exhibited trough
concentrations of 20 mg/liter. Likewise, when AGA infants
were to receive the recommended dosage for SGA infants,
about 20% of them failed to achieve a trough level of 5
mg/liter, and fewer than 75% of them attained the target
AUC24/MIC ratio. The final dosing recommendations for in-
termittent vancomycin intravenous administration are pre-
sented in Table 5.
DISCUSSION
This study presented some new findings with respect to the
pharmacokinetic disposition of vancomycin in premature Ma-
laysian infants within the first month of life, based on retro-
spective drug monitoring data. Both SGA status and PMA
were shown to influence the CL of vancomycin, independent of
size, by scaling the infants’ weight to that of a 70-kg standard
adult subject during model development. Allometric scaling,
based on fractal geometry theory, has received increased ac-
ceptance as a convenient size standard in pharmacokinetics
(22). Exponents of 0.75 and 1 for the allometric scaling of
weight on clearance and volume of distribution, respectively,
were assumed instead of being estimated, because one cannot
reliably estimate exponents of the allometric model unless
there is a very large weight range (4).
Both one- and two-compartment models have previously
been used to describe vancomycin pharmacokinetics in neo-
nates (3, 6, 12). The data in the current study did not support
precise estimation of parameter values in a two-compartment
model. The volume of distribution of vancomycin estimated in
this study is comparable to that previously reported, while the
clearance was lower than that estimated to occur in the Cau-
FIG. 2. Estimated clearance in relation to the PMA and PNA strat-
ified into weeks for study subjects. The solid lines are the median
clearance values, while the shaded areas represent the 95th-percentile
intervals.
FIG. 3. Diagnostic scatter plots of observations versus pre-Bayesian estimations and observations versus post-Bayesian estimations for the
final model. The broken lines represent the line of identity. Regression y  0.8242x  2.816, R2  0.77, imprecision  5.97 (95% confidence
interval [CI], 5.51 to 6.42) mg/liter, and bias  0.03 (95% CI, 
0.17 to 0.24) mg/liter for pre-Bayesian estimation, while regression y 
1.0915x 
 0.0042, R2  0.89, imprecision  4.13 (95% CI, 3.75 to 4.51) mg/liter, and bias  
0.30 (95% CI, 
0.16 to 
0.44) mg/liter for
post-Bayesian estimation.
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casian patients (3, 6, 12). Nonetheless, a degree of caution
must be exercised when the parameter values obtained from
various study groups are compared, as different models were
used in parameter value estimation. A more reliable way of
comparing these estimated parameter values might be to pool
the data and analyze them simultaneously.
Decreased vancomycin clearance levels in small-for-gesta-
tional-age Caucasian infants were reported in two recent stud-
ies (2, 15). Compared with the proportions used in these two
earlier studies, there was a markedly increased proportion of
SGA infants enrolled in this study, which may partly explain
the differences in the findings. Frattarelli et al. (15) ignored the
influence of other potential covariates, such as weight and
PMA, in assessing the impact of SGA status on vancomycin
clearance. Notwithstanding the slightly different standards
used for defining SGA status (13, 29, 38), genetic differences,
cultural factors, maternal nutritional statuses, and perinatal
infection rates in Malaysian facilities may account for the
larger proportion of SGA infants enrolled in the present study.
Vancomycin is eliminated chiefly by glomerular filtration.
Tubular damage arising from chronic fetal hypoxia in intra-
uterine-growth-retardation-complicated pregnancies (30), re-
duced glomerular filtration rate, and impaired sodium conser-
vation in early postnatal life in SGA premature neonates (32)
would markedly reduce the clearance. Moreover, a significant
reduction in the number of functional nephrons in intrauter-
ine-growth-retardation-affected neonates (21, 35) led us ini-
tially to predict that elevated serum creatinine concentration
could be correlated with reduced vancomycin CL. Indeed, sev-
eral previous studies reported that serum creatinine concen-
tration was a significant predictor of the elimination of this
antibiotic in the newborn (3, 6, 25). Although serum creatinine
concentration was presently a predictor of CL when screened
alone, its addition to the final model resulted in a markedly
inferior fit suggesting overparameterization of the structural
model. Clearly, the relationship among these variables with
respect to vancomycin CL in the developmental physiology of
premature infants is complex. For example, it is known that
from several days to weeks after birth, there are elevated cre-
atinine concentrations inappropriate to age and muscle mass in
very preterm neonates. While placental transfer of maternal
creatinine may contribute over the first day or two of life, a
complex pattern of reabsorption and secretion of creatinine
along the leaky immature renal tubules and vasculature during
this period offers a more likely explanation (19), especially
since 80% of the observations were provided by infants during
the first month of life. A marked nonlinear increase in CL as a
function of increasing PMA was clearly demonstrated (Fig. 2),
reflecting the rapid functional development of eliminating or-
gans observed when the infants were approaching full-term
gestation.
Protein binding may hinder distribution of antimicrobial
agents in tissues and hamper delivery of drug molecules to the
site of action. Vancomycin is 25 to 35% protein bound, mainly
to albumin and IgA. An in vitro study indicated that high
albumin concentrations inhibit vancomycin bactericidal ac-
tivity (17), but the clinical impact of changing plasma protein
TABLE 3. Estimated population pharmacokinetic parameter values
for the final model and for 1,000 bootstrap runs
Parametera
Median value
for final
model
Value (2.5th–97.5th
percentile) for 1,000
bootstrap runs
Structural model parameters
CLpop (liters h

1) 1.00b 0.982 (0.474–1.130)b
Vpop (liters) 36.6
b 36.6 (34.9–38.3)b
Scaling factor of PMA on CL 3.16 3.14 (2.52–3.77)
Scaling factor of SGA on CL 0.83 0.84 (0.74–1.85)
Scaling factor of AGA on CL 1.03 1.04 (0.91–2.23)
Variance model parameters
CL 20.5 20.2 (16.4–23.9)
V 12.6 12.3 (6.0–17.2)
BOV 16.7 16.3 (11.2–20.8)
proportional 22.9 23.0 (19.7–26.3)
additive (mg/liter) 1.51 1.50 (0.89–1.78)
a CLpop, population value for clearance; Vpop, population estimate for volume
of distribution; PMA, postmenstrual age; SGA, small for gestational age; AGA,
appropriate for gestational age; BOV, between-occasion variability of CL; ,
coefficient of variation (CV%); , unexplained residual variability (CV%).
b These parameter values were standardized to the size of a 70-kg adult with
allometric exponents of 0.75 and 1 for clearance and volume of distribution,
respectively.
FIG. 4. Box plots of the distributions of observed (Obs) and predicted (Pred) predose and postdose concentrations from 1,000 simulations from
the final population model. The bold horizontal bars in the middle show the median values of vancomycin concentrations, while the outer
boundaries of the boxes represent the ranges of the 25th and the 75th percentiles (interquartile ranges). The whiskers indicate the maximum and
the minimum values of the concentrations. Outliers are not shown in these plots.
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binding has not been demonstrated for adult patients (1). In
the present study, total (bound-plus-unbound) concentrations
were measured. The free fraction is constant from 2 to 80
mg/liter, which encompasses all concentrations in our data (9).
Thus, dosage adjustment for attainment of targets on the basis
of monitored total levels is valid and independent of protein
binding.
In linking the pharmacodynamics of vancomycin killing and
antibiotic systemic exposure, a target AUC24/MIC index of at
least 400 was proposed for the treatment of invasive MRSA on
the basis of the work of Moise-Broder et al. (28) and Frymoyer
et al. (16) and was reinforced in a very recent consensus paper
on vancomycin practice guidelines (34). Therefore, it was pru-
dent to consider an AUC24/MIC target in addition to the
traditional targeted peak (postinfusion) and trough (preinfu-
sion) concentrations for any vancomycin dosage recommenda-
tion in order to minimize treatment failure, even though this
dosing approach has been validated neither for adults nor for
neonates. The ratio will probably need to be greater and would
differ for babies with various degrees of prematurity, but this
was beyond the scope of the present study.
The most prevalent pathogen in our SCN is methicillin-
resistant Staphylococcus epidermidis (MRSE). Meropenem is
often coadministered with vancomycin, and synergism between
carbapenems and vancomycin has been documented (26). As
such, the regimens developed from the population pharmaco-
kinetic data in this study were predicated on an MIC of 1
mg/liter. The emergence of Staphylococcus warneri (7), which
has reduced glycopeptide susceptibility (MIC  2 mg/liter),
may warrant proportionately higher vancomycin doses for
treating nosocomial infections caused by this organism in neo-
natal intensive care units. The results also indicated that a
lower maintenance dose is required for infants who are small
for their gestational ages than for appropriate-for-gestational-
age infants in order to maintain serum trough concentrations
between 5 mg/liter and 20 mg/liter and an AUC24/MIC target
greater than 400.
From a pharmacokinetic viewpoint, vancomycin serum con-
centration monitoring is still recommended for these infants,
especially since we established from the variability model that
the day-to-day variability (i.e., BOV) in CL was less than the
variability between infants (i.e., BSV), which facilitates the
adjustment of maintenance dosages on the basis of monitoring
data; however, this would not be the case if the BOV were
markedly greater than the BSV (8).
Conclusion. The population pharmacokinetics of vancomycin
have been described for premature Malaysian infants. Weight
and postmenstrual age were important contributing factors for
explaining variability in clearance, while weight alone was the
most significant predictor for volume of distribution. Infants
who were small for their gestational ages exhibited a 20%
reduction in vancomycin clearance, compared to the level for
appropriate-for-gestational-age infants. Dosing regimens in-
corporating weight, PMA, and SGA status to target an AUC24/
MIC ratio of 400 are likely to improve clinical outcome,
supported by routine serum concentration monitoring.
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